Less Ads, More Data, More Tools Register for FREE

Omega Diagnostic Profit Up, Optimistic As It Ramps Up Visitect CD4 Commercialisation

Mon, 23rd Jun 2014 09:58

LONDON (Alliance News) - Omega Diagnostics Group PLC Monday posted a rise in pretax profit for the year to end-March, boosted by strong growth in its food intolerance products, as it prepares for commercialisation of its Visitect CD4 tests for infectious diseases.

The medical diagnostics company posted a pretax profit of GBP543,041, up from GBP276,224 in the previous year, as revenue rose to GBP11.6 million from GBP11.3 million.

Revenue growth was driven by a strong performance from the company's food intolerance division, boosted by 35% sales growth for its Food Detective products and 15% sales growth for its Genarrayt reagent products.

The company has continued to develop its programme to launch allergy tests on Immunodiagnostic Systems Holdings PLC's IDS-iSYS automated analyser, although it noted that it has taken "longer to reach a marketable product than first anticipated."

During the year Omega Diagnostics established a UK facility for the production of Visitect CD4, and will shortly begin an interior build of a manufacturing base in Pune, India.

The company said its trading in the new financial year to-date is in line with expectations, with growth in food intolerance offsetting a decline in Allergy and Infectious Disease testing.

Omega expressed confidence for the new financial year as its Visitect CD4 test moves closer to commercialisation. The company said that the sales potential for the product is high, however, there are some hurdles to overcome including individual country evaluations and approvals.

"Our future landscape is brightened, as well as dominated, by the prospects for our Visitect CD4 test, which is now well into its field trials," said Chairman David Evans in a statement.

Whilst the company is confident for the prospects of the product, it remains cautious, noting that as the product's success will be primarily based on global tenders, it will be affected by the availability of funds and the needs of governments.

As a result of this uncertainty, the company said it had erred on the side of caution in terms of revenues and building its overhead base ahead of the products launch.

Shares in Omega Diagnostics were trading down 16%% at 23.82 pence Monday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

Related Shares

More News
6 Sep 2023 16:40

TRADING UPDATES: Solid State sees strong orders in security & defence

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

30 Aug 2023 15:44

UK shareholder meetings calendar - next 7 days

22 Aug 2023 10:41

Omega Diagnostics finance director steps down with immediate effect

(Alliance News) - Omega Diagnostics Group PLC on Tuesday said that Group Finance Director Chris Lea has stepped down with immediate effect, as he is b...

3 Aug 2023 14:08

Omega Diagnostics says revenue and loss hurt by operational issues

(Alliance News) - Omega Diagnostics Group PLC on Thursday said its annual loss widened as operational difficulties caused its revenue to plunge.

27 Jul 2023 15:40

UK earnings, trading statements calendar - next 7 days

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.